Company news
Hinova Pharmaceuticals, Inc. news in 2026
Hinova Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
(688302)"HINOVA PHARMACEUTICALS INC."Announcement on Voluntary Disclosure of Obtaining U.S. FDA Approval for Clinical Trial Application for HP570 Tablets
November 3, 2026
(688302)"HINOVA PHARMACEUTICALS INC."Announcement on Voluntary Disclosure of Phase IIa Clinical Trial Data of HP515 Tablets Being Accepted as a Late-Breaking Abstract at the Annual Meeting of the American Association for the Study of Liver Diseases
October 8, 2026
Announcement on the Board Secretary's Receipt of the Qualification Training Certificate and Official Assumption of Duties
September 23, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
September 11, 2026
Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 8, 2026
Announcement on Public Solicitation of Voting Rights by CHINA SECURITIES INVESTOR SERVICES CENTER CO., LTD.
August 27, 2026
Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors
August 26, 2026
Voluntary Disclosure Announcement on Receipt of Notice of Approval for Initiation of a Phase III Clinical Trial of Deuterated Enzalutamide Soft Capsules for High-risk Biochemical Recurrence (BCR) Prostate Cancer
July 15, 2026
Announcement on Reply to Inquiry Letter for Information Disclosure Supervision of 2025 Annual Report
June 26, 2026
Announcement on Voluntary Disclosure of Final Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)
June 15, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 15, 2026
Announcement on Voluntary Disclosure of Interim Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)
April 27, 2026
Notice on Convening the 2025 Annual General Meeting
April 24, 2026
Announcement on Change of Sponsor Representative
April 20, 2026
Announcement on Voluntary Disclosure of Completion of Inclusion of All Participants in Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)
March 3, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on the Company's Successful GMP Compliance Inspection and the Amendment of Its Drug Manufacturing License
February 1, 2026
Earnings Preannouncement for 2025
January 30, 2026